Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 2026
4 Articles
4 Articles
Celltrion announced on the 15th that it will introduce its portfolio of inflammatory bowel disease (IBD) treatments, including the autoimmune disease treatment 'Remsima SC' (active ingredient: infliximab), at the '2026 European Gastroenterology Week (UEG Week)' held in Spain. UEG Week, taking place from the 17th to the 20th of this month (local time) in Barcelona, Spain, is an academic conference that shares the latest clinical research and trea…
In collaboration with the daily newspaper l'Adige we receive and publish the link of the following news. Opinione thanks the publisher for the multimedia partnership. /// Celltrion will bring to the spotlight RemsimaTM SC (infliximab subcutaneous) and a wider portfolio for IBDs at UG Week 2026. Link to the news
Celltrion will present its extensive IBD portfolio, including Remsima™ IV, Remsima™ SC, the recently launched Remsima™ IV liquid formula, Steqeyma™ and Yuflyma™. Symposium and ‘Meet the Experts’ sessions will highlight long-term clinical evidence and field experiences with SC (subcutaneous) infliximab (Remsima™ SC) in various IBD patient scenarios. INCHEON, South Korea–(BUSINESS WIRE)– Celltrion, Inc. (KRX:068270) announced […]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
